This company seems to have been delisted
Reason: Delisted by Nasdaq
Last recorded trade on: February 22, 2023
Source: https://www.globenewswire.com/en/news-release/2022/12/28/2580400/6948/en/Delisting-of-Securities-of-Tuscan-Holdings-Corp-II-Clovis-Oncology-Inc-ZyVersa-Therapeutics-Inc-Otonomy-Inc-and-Forward-Pharma-A-S-from-The-Nasdaq-Stock-Market.html
Reason: Delisted by Nasdaq
Last recorded trade on: February 22, 2023
Source: https://www.globenewswire.com/en/news-release/2022/12/28/2580400/6948/en/Delisting-of-Securities-of-Tuscan-Holdings-Corp-II-Clovis-Oncology-Inc-ZyVersa-Therapeutics-Inc-Otonomy-Inc-and-Forward-Pharma-A-S-from-The-Nasdaq-Stock-Market.html
Clovis Oncology
CLVS
$0.14
Share price
0.00%
Change (1 day)
-94.87%
Change (1 year)
Categories
Clovis Oncology (CLVS) - P/B ratio
P/B ratio as of March 2025 : -0.0282
According to Clovis Oncology's latest financial reports the company has a price-to-book ratio of 0.0884849.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Clovis Oncology - P/B ratio (from 2011 to 2022)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2022-12-31 | -0.0282 | -97.76% |
| 2021-12-31 | -1.25 | -59.98% |
| 2020-12-31 | -3.14 | -4.63% |
| 2019-12-31 | -3.29 | -150.78% |
| 2018-12-31 | 6.47 | -30.49% |
| 2017-12-31 | 9.31 | -101.97% |
| 2016-12-31 | -472 | -10661.86% |
| 2015-12-31 | 4.47 | -22.17% |
| 2014-12-31 | 5.74 | 39.83% |
| 2013-12-31 | 4.10 | 30.64% |
| 2012-12-31 | 3.14 | 35.62% |
| 2011-12-31 | 2.32 | |
| 2010-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | P/B ratio differencediff. | Country |
|---|---|---|---|
 | 2.41 | -8,651.54% | 🇺🇸 USA |
 | 5.61 | -20,002.40% | 🇬🇧 UK |
 | 1.61 | -5,805.70% | 🇺🇸 USA |
 | 5.53 | -19,724.16% | 🇺🇸 USA |
 | 108 | -383,659.84% | 🇺🇸 USA |
 | 51.6 | -183,382.92% | 🇺🇸 USA |